SOX2 and adenocarcinoma: on 146 NSCLC cases, squamous cell carcinoma (72%) expressed SOX2 much more than adenocarcinoma (8%), and the overexpression of SOX2 may be associated with a good prognosis for squamous cell carcinoma (26–28).